Medication Summary

No specific antiviral medication is available to treat dengue. The treatment of dengue fever is symptomatic and supportive in nature. Bed rest and mild analgesic-antipyretic therapy often are helpful in relieving lethargy, malaise, and fever associated with the disease. Acetaminophen (paracetamol) is recommended for treatment of pain and fever. Aspirin, other salicylates, and nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided.

Patients with dengue hemorrhagic fever or dengue shock syndrome may require intravenous volume replacement. Plasma volume expanders can be used in patients who do not respond to isotonic fluids.

Dengue vaccine was approved by the FDA in 2019 for individuals aged 9-16 years with laboratory-confirmed previous dengue infection who live in endemic areas.

Class Summary

These agents are used to reduce fever. They inhibit prostaglandin synthesis in the central nervous system. They also inhibit hypothalamic heat-regulating center, which in turn promotes the return of the set-point temperature to normal.

Acetaminophen (Tylenol, Feverall, Acephen, Mapap)

View full drug information

Acetaminophen (paracetamol) reduces fever by acting directly on hypothalamic heat-regulating centers, which increases dissipation of body heat via vasodilation and sweating. It is used in dengue infections to relieve pain and lower temperature when fever is thought to contribute to patient discomfort.

Class Summary

Plasma volume expanders are used in the treatment of intravascular volume deficits or shock to restore intravascular volume, blood pressure, and tissue perfusion.

Dextran 40 (LMD)

View full drug information

Dextran 40 is a polymer of glucose. When infused, it increases intravascular volume, blood pressure, and capillary perfusion. It is used to restore intravascular volume when isotonic crystalloid administration is inadequate for that purpose.

Albumin (Albuminar-5, Buminate, Plasbumin 5)

View full drug information

Human albumin is a sterile solution of albumin, which is the major plasma protein responsible for the colloid oncotic pressure of blood. It is pooled from blood, serum, plasma, or placenta from healthy donors. Infusion of albumin results in a shift of fluid from the extracellular space into the bloodstream, thereby decreasing hemoconcentration and blood viscosity.

Albumin may be administered wide open when treating shock. Patient response must be assessed before repeating the dose.

Hetastarch (Hespan, Hextend)

View full drug information

Hydroxyethyl starch is a sterile solution of the starch responsible for the colloid oncotic pressure of blood. Hetastarch produces volume expansion through its highly colloidal starch structure.

Class Summary

Elicits dengue-specific immune responses against the 4 dengue virus serotypes (ie, serotypes 1, 2, 3, and 4).

Dengue vaccine (Dengvaxia)

View full drug information

Indicated for prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4 in individuals aged 9-16 years with laboratory-confirmed previous dengue infection who live in endemic areas. It is approved only in individuals previously infected by any dengue virus serotype or in whom this information is unknown. Persons not previously infected are at an increased risk of severe dengue disease when vaccinated and subsequently infected with dengue virus. Immunization is a series of 3 SC injections administered 6 months apart.

Questions

Santos LLM, de Aquino EC, Fernandes SM, Ternes YMF, Feres VCR. Dengue, chikungunya, and Zika virus infections in Latin America and the Caribbean: a systematic review. Rev Panam Salud Publica. 2023. 47:e34. [QxMD MEDLINE Link].
Schaefer TJ, Panda PK, Wolford RW. Dengue Fever. StatPearls. 2023 Jan. [QxMD MEDLINE Link]. [Full Text].
Tayal A, Kabra SK, Lodha R. Management of Dengue: An Updated Review. Indian J Pediatr. 2023 Feb. 90 (2):168-177. [QxMD MEDLINE Link].
Kok BH, Lim HT, Lim CP, Lai NS, Leow CY, Leow CH. Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy. Virus Res. 2023 Jan 15. 324:199018. [QxMD MEDLINE Link].
World Health Organization. Dengue and severe dengue fact sheet. WHO. Available at http://www.who.int/mediacentre/factsheets/fs117/en/. April 2017; Accessed: April 11, 2023.
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013 Apr 25. 496 (7446):504-7. [QxMD MEDLINE Link].
Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012. 6 (8):e1760. [QxMD MEDLINE Link].
Wilson ME, Chen LH. Dengue: update on epidemiology. Curr Infect Dis Rep. 2015 Jan. 17 (1):457. [QxMD MEDLINE Link].
WHO. Ten threats to global health in 2019. World Health Organization. Available at https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. 2019; Accessed: April 11, 2023.
Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol. 2008. 62:71-92. [QxMD MEDLINE Link].
Statler J, Mammen M, Lyons A, Sun W. Sonographic findings of healthy volunteers infected with dengue virus. J Clin Ultrasound. 2008 Sep. 36(7):413-7. [QxMD MEDLINE Link].
Gubler DJ. Cities spawn epidemic dengue viruses. Nat Med. 2004 Feb. 10(2):129-30. [QxMD MEDLINE Link].
Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med Clin North Am. 2008 Nov. 92(6):1377-90, x. [QxMD MEDLINE Link].
Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA, et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol. 2014 Mar. 22 (3):138-46. [QxMD MEDLINE Link]. [Full Text].
Halstead SB. Dengue. Lancet. 2007 Nov 10. 370(9599):1644-52. [QxMD MEDLINE Link].
Chowell G, Torre CA, Munayco-Escate C, Suárez-Ognio L, López-Cruz R, Hyman JM. Spatial and temporal dynamics of dengue fever in Peru: 1994-2006. Epidemiol Infect. 2008 Dec. 136(12):1667-77. [QxMD MEDLINE Link].
Osterweil N. Dengue 'Under-recognized' as Source of Febrile Illness in US. Medscape Medical News. Jan 23 2014. Available at http://www.medscape.com/viewarticle/819656. Accessed: April 11, 2023.
Sharp TM, Gaul L, Muehlenbachs A, Hunsperger E, Bhatnagar J, Lueptow R, et al. Fatal hemophagocytic lymphohistiocytosis associated with locally acquired dengue virus infection - new Mexico and Texas, 2012. MMWR Morb Mortal Wkly Rep. 2014 Jan 24. 63(3):49-54. [QxMD MEDLINE Link].
Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006 Jan 12. 354(2):119-30. [QxMD MEDLINE Link].
Liu-Helmersson J, Quam M, Wilder-Smith A, Stenlund H, Ebi K, Massad E, et al. Climate Change and Aedes Vectors: 21st Century Projections for Dengue Transmission in Europe. EBioMedicine. 2016 May. 7:267-77. [QxMD MEDLINE Link].
CDC. Imported dengue--United States, 1997 and 1998. MMWR Morb Mortal Wkly Rep. 2000 Mar 31. 49(12):248-53. [QxMD MEDLINE Link]. [Full Text].
Engelthaler DM, Fink TM, Levy CE, Leslie MJ. The reemergence of Aedes aegypti in Arizona. Emerg Infect Dis. 1997 Apr-Jun. 3(2):241-2. [QxMD MEDLINE Link]. [Full Text].
Chye JK, Lim CT, Ng KB, et al. Vertical transmission of dengue. Clin Infect Dis. 1997 Dec. 25(6):1374-7. [QxMD MEDLINE Link].
Wagner D, de With K, Huzly D, Hufert F, Weidmann M, Breisinger S, et al. Nosocomial acquisition of dengue. Emerg Infect Dis. 2004 Oct. 10(10):1872-3. [QxMD MEDLINE Link].
Arragain L, Dupont-Rouzeyrol M, O'Connor O, Sigur N, Grangeon JP, Huguon E, et al. Vertical Transmission of Dengue Virus in the Peripartum Period and Viral Kinetics in Newborns and Breast Milk: New Data. J Pediatric Infect Dis Soc. 2017 Nov 24. 6 (4):324-331. [QxMD MEDLINE Link].
Lalle E, Colavita F, Iannetta M, Gebremeskel Teklè S, Carletti F, Scorzolini L, et al. Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy, January 2018. Euro Surveill. 2018 May. 23 (18):[QxMD MEDLINE Link].
Liew CH. The first case of sexual transmission of dengue in Spain. J Travel Med. 2020 Feb 3. 27 (1):[QxMD MEDLINE Link].
Dejnirattisai W, Duangchinda T, Lin CL, Vasanawathana S, Jones M, Jacobs M, et al. A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J Immunol. 2008 Nov 1. 181(9):5865-74. [QxMD MEDLINE Link].
Halstead SB, Heinz FX, Barrett AD, Roehrig JT. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine. 2005 Jan 4. 23(7):849-56. [QxMD MEDLINE Link].
Limjindaporn T, Wongwiwat W, Noisakran S, Srisawat C, Netsawang J, Puttikhunt C, et al. Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production. Biochem Biophys Res Commun. 2009 Feb 6. 379(2):196-200. [QxMD MEDLINE Link].
Zhang JL, Wang JL, Gao N, Chen ZT, Tian YP, An J. Up-regulated expression of beta3 integrin induced by dengue virus serotype 2 infection associated with virus entry into human dermal microvascular endothelial cells. Biochem Biophys Res Commun. 2007 May 11. 356(3):763-8. [QxMD MEDLINE Link].
Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. Virology. 1999 Apr 25. 257(1):1-6. [QxMD MEDLINE Link].
Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg. 2006 Jan. 74(1):142-7. [QxMD MEDLINE Link].
Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis. 2006 Oct. 19(5):429-36. [QxMD MEDLINE Link].
Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007 Feb. 13(2):282-6. [QxMD MEDLINE Link].
Restrepo BN, Ramirez RE, Arboleda M, Alvarez G, Ospina M, Diaz FJ. Serum levels of cytokines in two ethnic groups with dengue virus infection. Am J Trop Med Hyg. 2008 Nov. 79(5):673-7. [QxMD MEDLINE Link].
Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest. 2004 Apr. 113(7):946-51. [QxMD MEDLINE Link].
de Macedo FC, Nicol AF, Cooper LD, Yearsley M, Pires AR, Nuovo GJ. Histologic, viral, and molecular correlates of dengue fever infection of the liver using highly sensitive immunohistochemistry. Diagn Mol Pathol. 2006 Dec. 15(4):223-8. [QxMD MEDLINE Link].
Shah I. Dengue and liver disease. Scand J Infect Dis. 2008. 40(11-12):993-4. [QxMD MEDLINE Link].
Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010 May 7. 328(5979):745-8. [QxMD MEDLINE Link].
Schmidt AC. Response to dengue fever--the good, the bad, and the ugly?. N Engl J Med. 2010 Jul 29. 363(5):484-7. [QxMD MEDLINE Link].
Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Ennis FA. High levels of interferon alpha in the sera of children with dengue virus infection. Am J Trop Med Hyg. 1993 Feb. 48(2):222-9. [QxMD MEDLINE Link].
Ojha A, Nandi D, Batra H, Singhal R, Annarapu GK, Bhattacharyya S, et al. Platelet activation determines the severity of thrombocytopenia in dengue infection. Sci Rep. 2017 Jan 31. 7:41697. [QxMD MEDLINE Link].
Hottz ED, Oliveira MF, Nunes PC, Nogueira RM, Valls-de-Souza R, Da Poian AT, et al. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. J Thromb Haemost. 2013 May. 11 (5):951-62. [QxMD MEDLINE Link].
Wang E, Ni H, Xu R, Barrett AD, Watowich SJ, Gubler DJ. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol. 2000 Apr. 74(7):3227-34. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention Web site. CDC traveler's health page. Dengue. CDC. Available at http://www.cdc.gov/Dengue/travelOutbreaks/. Accessed: April 11, 2023.
Chen WS, Wong CH, Cillekens L. Dengue antibodies in a suburban community in Malaysia. Med J Malaysia. 2003 Mar. 58(1):142-3. [QxMD MEDLINE Link].
Istúriz RE, Gubler DJ, Brea del Castillo J. Dengue and dengue hemorrhagic fever in Latin America and the Caribbean. Infect Dis Clin North Am. 2000 Mar. 14(1):121-40, ix. [QxMD MEDLINE Link].
Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008 Sep 24. 2(9):e300. [QxMD MEDLINE Link]. [Full Text].
Centers for Disease Control and Prevention (CDC). Travel-associated Dengue surveillance - United States, 2006-2008. MMWR Morb Mortal Wkly Rep. 2010 Jun 18. 59(23):715-9. [QxMD MEDLINE Link]. [Full Text].
Centers for Disease Control and Prevention (CDC). Locally acquired Dengue--Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep. 2010 May 21. 59(19):577-81. [QxMD MEDLINE Link].
Rey JR. Dengue in Florida (USA). Insects. 2014 Dec 16. 5 (4):991-1000. [QxMD MEDLINE Link].
Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. Dengue viral infections. Postgrad Med J. 2004 Oct. 80(948):588-601. [QxMD MEDLINE Link]. [Full Text].
Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ. 2005 Apr. 83(4):308-14. [QxMD MEDLINE Link]. [Full Text].
World Health Organization. Dengue and Severe Dengue. WHO. Available at https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. March 17, 2023; Accessed: April 11. 2023.
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013 Apr 25. 496 (7446):504-7. [QxMD MEDLINE Link].
Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012. 6 (8):e1760. [QxMD MEDLINE Link].
Lin CC, Huang YH, Shu PY, et al. Characteristic of dengue disease in Taiwan: 2002-2007. Am J Trop Med Hyg. 2010 Apr. 82(4):731-9. [QxMD MEDLINE Link]. [Full Text].
Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet. 2007 Apr 28. 369(9571):1452-9. [QxMD MEDLINE Link].
Anker M, Arima Y. Male-female differences in the number of reported incident dengue fever cases in six Asian countries. Western Pac Surveill Response J. 2011 Apr. 2 (2):17-23. [QxMD MEDLINE Link].
Lahiri M, Fisher D, Tambyah PA. Dengue mortality: reassessing the risks in transition countries. Trans R Soc Trop Med Hyg. 2008 Oct. 102(10):1011-6. [QxMD MEDLINE Link].
Beatty ME, Beutels P, Meltzer MI, et al. Health economics of dengue: a systematic literature review and expert panel's assessment. Am J Trop Med Hyg. 2011 Mar. 84(3):473-88. [QxMD MEDLINE Link]. [Full Text].
Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg. 2011 Feb. 84(2):200-7. [QxMD MEDLINE Link]. [Full Text].
Suaya JA, Shepard DS, Siqueira JB, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg. 2009 May. 80(5):846-55. [QxMD MEDLINE Link].
WHO. Dengue and Severe Dengue. World Health Organization. Available at https://www.who.int/health-topics/dengue-and-severe-dengue. Accessed: April 11, 2023.
Sanjay S, Wagle AM, Au Eong KG. Dengue optic neuropathy. Ophthalmology. 2009 Jan. 116(1):170; author reply 170. [QxMD MEDLINE Link].
Teves Maria A. Wrong treatment most common cause of dengue fatality. ABS/CBN News. Available at http://www.abs-cbnnews.com/nation/09/03/09/wrong-treatment-most-common-cause-dengue-fatality. Accessed: April 11, 2023.
Bottieau E, Clerinx J, Van den Enden E, Van Esbroeck M, Colebunders R, Van Gompel A. Fever after a stay in the tropics: diagnostic predictors of the leading tropical conditions. Medicine (Baltimore). 2007 Jan. 86(1):18-25. [QxMD MEDLINE Link].
Malhotra N, Chanana C, Kumar S. Dengue infection in pregnancy. Int J Gynaecol Obstet. 2006 Aug. 94(2):131-2. [QxMD MEDLINE Link].
Singh N, Sharma KA, Dadhwal V, Mittal S, Selvi AS. A successful management of dengue fever in pregnancy: report of two cases. Indian J Med Microbiol. 2008 Oct-Dec. 26(4):377-80. [QxMD MEDLINE Link].
Warrilow D, Northill JA, Pyke A, Smith GA. Single rapid TaqMan fluorogenic probe based PCR assay that detects all four dengue serotypes. J Med Virol. 2002 Apr. 66(4):524-8. [QxMD MEDLINE Link].
Kong YY, Thay CH, Tin TC, Devi S. Rapid detection, serotyping and quantitation of dengue viruses by TaqMan real-time one-step RT-PCR. J Virol Methods. 2006 Dec. 138(1-2):123-30. [QxMD MEDLINE Link].
Trung DT, Thao le TT, Hien TT, et al. Liver involvement associated with dengue infection in adults in Vietnam. Am J Trop Med Hyg. 2010 Oct. 83(4):774-80. [QxMD MEDLINE Link]. [Full Text].
Potts JA, Rothman AL. Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. Trop Med Int Health. 2008 Nov. 13(11):1328-40. [QxMD MEDLINE Link]. [Full Text].
Lima EQ, Nogueira ML. Viral hemorrhagic fever-induced acute kidney injury. Semin Nephrol. 2008 Jul. 28(4):409-15. [QxMD MEDLINE Link].
Lombardi R, Yu L, Younes-Ibrahim M, Schor N, Burdmann EA. Epidemiology of acute kidney injury in Latin America. Semin Nephrol. 2008 Jul. 28(4):320-9. [QxMD MEDLINE Link].
Chaterji S, Allen JC Jr, Chow A, Leo YS, Ooi EE. Evaluation of the NS1 rapid test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults. Am J Trop Med Hyg. 2011 Feb. 84(2):224-8. [QxMD MEDLINE Link]. [Full Text].
Wichmann O, Stark K, Shu PY, Niedrig M, Frank C, Huang JH. Clinical features and pitfalls in the laboratory diagnosis of dengue in travellers. BMC Infect Dis. 2006. 6:120. [QxMD MEDLINE Link].
Domingo C, de Ory F, Sanz JC, Reyes N, Gascón J, Wichmann O, et al. Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers. Diagn Microbiol Infect Dis. 2009 Sep. 65(1):42-8. [QxMD MEDLINE Link].
Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N, Kalayanarooj S. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J. 2007 Apr. 26(4):283-90; discussion 291-2. [QxMD MEDLINE Link].
Santhosh VR, Patil PG, Srinath MG, Kumar A, Jain A, Archana M. Sonography in the diagnosis and assessment of dengue Fever. J Clin Imaging Sci. 2014. 4:14. [QxMD MEDLINE Link]. [Full Text].
Srikiatkhachorn A, Gibbons RV, Green S, et al. Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, 1994-2005. Clin Infect Dis. 2010 Apr 15. 50(8):1135-43. [QxMD MEDLINE Link]. [Full Text].
Setiati TE, Mairuhu AT, Koraka P, Supriatna M, Mac Gillavry MR, Brandjes DP, et al. Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infect Dis. 2007 Mar 26. 7:22. [QxMD MEDLINE Link]. [Full Text].
Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics. 1993 Jul. 92(1):111-5. [QxMD MEDLINE Link].
Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005 Sep 1. 353(9):877-89. [QxMD MEDLINE Link].
Yadav SP, Sachdeva A, Gupta D, Sharma SD, Kharya G. Control of massive bleeding in dengue hemorrhagic fever with severe thrombocytopenia by use of intravenous anti-D globulin. Pediatr Blood Cancer. 2008 Dec. 51(6):812-3. [QxMD MEDLINE Link].
Waduge R, Malavige GN, Pradeepan M, Wijeyaratne CN, Fernando S, Seneviratne SL. Dengue infections during pregnancy: a case series from Sri Lanka and review of the literature. J Clin Virol. 2006 Sep. 37(1):27-33. [QxMD MEDLINE Link].
Ismail NA, Kampan N, Mahdy ZA, Jamil MA, Razi ZR. Dengue in pregnancy. Southeast Asian J Trop Med Public Health. 2006 Jul. 37(4):681-3. [QxMD MEDLINE Link].
Billingsley PF, Foy B, Rasgon JL. Mosquitocidal vaccines: a neglected addition to malaria and dengue control strategies. Trends Parasitol. 2008 Sep. 24(9):396-400. [QxMD MEDLINE Link].
Erlanger TE, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological parameters in developing countries: a systematic review and meta-analysis. Med Vet Entomol. 2008 Sep. 22(3):203-21. [QxMD MEDLINE Link].
Kay B, Vu SN. New strategy against Aedes aegypti in Vietnam. Lancet. 2005 Feb 12-18. 365(9459):613-7. [QxMD MEDLINE Link].
Hanh TT, Hill PS, Kay BH, Quy TM. Development of a framework for evaluating the sustainability of community-based dengue control projects. Am J Trop Med Hyg. 2009 Feb. 80(2):312-8. [QxMD MEDLINE Link].
Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature. 2011 Aug 24. 476 (7361):454-7. [QxMD MEDLINE Link].
Lang J. Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol. 2009 Oct. 46 Suppl 2:S20-4. [QxMD MEDLINE Link].
World Health Organization. Dengue vaccine: WHO position paper – July 2016. Wkly Epidemiol Rec. 2016 Jul 29. 91 (30):349-64. [QxMD MEDLINE Link].
Aguiar M, Stollenwerk N, Halstead SB. The risks behind Dengvaxia recommendation. Lancet Infect Dis. 2016 Aug. 16 (8):882-3. [QxMD MEDLINE Link]. [Full Text].
Dengvaxia. European Medicines Agency. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/dengvaxia. 2018 Dec 18; Accessed: April 11, 2023.
Adams LE, Waterman S, Paz-Bailey G. Vaccination for Dengue Prevention. JAMA. 2022 Mar 1. 327 (9):817-818. [QxMD MEDLINE Link].
Dengvaxia (dengue vaccine) [package insert]. Swiftwater, PA: Sanofi Pasteur, Inc. May 2019. Available at [Full Text].
Monath TP. Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007 Nov 29. 357(22):2222-5. [QxMD MEDLINE Link].
Questions and Answers on Dengue Vaccines. World Health Organization. Available at https://www.who.int/immunization/research/development/dengue_q_and_a/en/. 2018 April 20; Accessed: April 11, 2023.
McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, et al. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg. 2008 Nov. 79(5):678-84. [QxMD MEDLINE Link]. [Full Text].
O'Brien J. 12th Annual Conference on Vaccine Research. Expert Rev Vaccines. 2009 Sep. 8(9):1139-42. [QxMD MEDLINE Link].
Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis. 2007 Jul 15. 45 Suppl 1:S56-60. [QxMD MEDLINE Link].
Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006 Spring. 19(1):10-32. [QxMD MEDLINE Link].
Larsen CP, Whitehead SS, Durbin AP. Dengue human infection models to advance dengue vaccine development. Vaccine. 2015 Sep 28. [QxMD MEDLINE Link].
Anker M, Arima Y. Male-female differences in the number of reported incident dengue fever cases in six Asian countries. Western Pac Surveill Response J. 2011 Apr. 2 (2):17-23. [QxMD MEDLINE Link].

Media Gallery

Drawing of Aedes aegypti mosquito. Courtesy of the Centers for Disease Control and Prevention (CDC).
Aedes albopictus. Courtesy of the Centers for Disease Control and Prevention (CDC).
Worldwide distribution of dengue in 2000. Courtesy of the Centers for Disease Control and Prevention (CDC).
Worldwide distribution of dengue in 2003. Courtesy of the Centers for Disease Control and Prevention (CDC).
Worldwide distribution of dengue in 2005. Courtesy of the Centers for Disease Control and Prevention (CDC).
Increasing rates of dengue infection by regions of the world. Courtesy of the World Health Organization (WHO).
Dengue transmission cycle. Courtesy of the Centers for Disease Control and Prevention (CDC).
Reinfestation by Aedes aegypti in the Americas after the 1970 (left) mosquito eradication program and most recent distribution as of 2002 (right). Courtesy of the Centers for Disease Control and Prevention (CDC).
A child with dengue hemorrhagic fever or dengue shock syndrome may present severely hypotensive with disseminated intravascular coagulation (DIC), as this severely ill pediatric ICU patient did. Crystalloid fluid resuscitation and standard DIC treatment are critical to the child's survival.
Delayed capillary refill may be the first sign of intravascular volume depletion. Hypotension usually is a late sign in children. This child's capillary refill at 6 seconds was delayed well beyond a normal duration of 2 seconds.
Signs of early coagulopathy may be as subtle as a guaiac test that is positive for occult blood in the stool. This test should be performed on all patients in whom dengue virus infection is suspected.
Aedes aegypti mosquito. Courtesy of Wikimedia Commons (https://commons.wikimedia.org/wiki/File:Aedes_aegypti.jpg; author Muhammad Mahdi Karim).
Global map of dengue risk. Frequent or continuous risk = frequent outbreaks or ongoing transmission. Sporadic or uncertain risk = variable and unpredictable risk, country-level data are unavailable. Courtesy of the Centers for Disease Control and Prevention (CDC) (https://www.cdc.gov/dengue/areaswithrisk/around-the-world.html).

of 13

Author

Darvin Scott Smith, MD, MSc, DTM&H, FIDSA Chief of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, Kaiser Permanente Medical Group

Darvin Scott Smith, MD, MSc, DTM&H, FIDSA is a member of the following medical societies: American Medical Association, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, International Society of Travel Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

David J Mariano, BS, MS MD Candidate, University of California, San Diego, School of Medicine

Disclosure: Nothing to disclose.

Micah Lynne Trautwein, BS MD Candidate, Geisel School of Medicine at Dartmouth

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Suzanne Moore Shepherd, MD, MS, DTM&H, FACEP, FAAEM Professor of Emergency Medicine, Education Officer, Department of Emergency Medicine, Hospital of the University of Pennsylvania; Director of Education and Research, PENN Travel Medicine; Medical Director, Fast Track, Department of Emergency Medicine

Suzanne Moore Shepherd, MD, MS, DTM&H, FACEP, FAAEM is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American Society of Tropical Medicine and Hygiene, International Society of Travel Medicine, Society for Academic Emergency Medicine, Wilderness Medical Society

Disclosure: Nothing to disclose.

Patrick B Hinfey, MD Emergency Medicine Residency Director, Department of Emergency Medicine, Newark Beth Israel Medical Center; Clinical Assistant Professor of Emergency Medicine, New York College of Osteopathic Medicine

Patrick B Hinfey, MD is a member of the following medical societies: American Academy of Emergency Medicine, Wilderness Medical Society, American College of Emergency Physicians, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

William H Shoff, MD, DTM&H Former Director, PENN Travel Medicine; Former Associate Professor, Department of Emergency Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine

William H Shoff, MD, DTM&H is a member of the following medical societies: American College of Physicians, American Society of Tropical Medicine and Hygiene, International Society of Travel Medicine, Society for Academic Emergency Medicine, Wilderness Medical Society

Disclosure: Nothing to disclose.

Acknowledgements

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa